Vivimed Labs consolidated revenue for the quarter came in at Rs. 282.5 crore, registering 6.6% yoy decline. This was primarily driven by 37% yoy decline in revenue from speciality chemical business.
EBITDA for the quarter fell by 2.7% yoy to Rs. 62.59 crore with a corresponding margin expansion of 89 bps. EBITDA margin for the quarter stood at 22.2%. This margin expansion was aided by 20% yoy decline in cost of materials.
The PAT for the quarter came in at Rs. 22 crore, yoy decline of 17.8%. This was due to 43% yoy rise in interest income.
Vivimed Labs Ltd ended at Rs. 117.10, down by 0.25 points or 0.21% from its previous closing of Rs. 117.35 on the BSE.
The scrip opened at Rs. 117.75 and touched a high and low of Rs. 121.95 and Rs. 116.75 respectively. A total of 7,92,394(NSE+BSE) shares were traded on the counter. The stock traded above its 50 DMA.
Start investing in Equities, Derivatives, Mutual Funds and Currency
Temporary Password will be sent to your Mobile No. / Email Address to reset your password.
Make smart financial decisions
Trusted by more than 25 Lakhs Indians
Research and Stocks
Strategy and Tools
Terms & Conditions
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in National Do Not Call Registry as laid down by Telecom Regulatory Authority of India will not be applicable for such information/ communication.